Correction — SOLVE FSHD invests $10 million in Vita Therapeutics, The Canadian Business Journal

VANCOUVER, British Columbia, October 13, 2022 (GLOBE NEWSWIRE) — Please note that the Vita Therapeutics embedded link in paragraph 1 has been updated in the release issued by SOLVE FSHD under the same heading today. Here is the fixed release:

Solve FSHD, A venture charity that accelerates the pace of innovation to accelerate the treatment of facioscapulohumeral muscular dystrophy (FSHD) announced today: Vita Therapeuticsa cell engineering company that harnesses the power of genetics to develop novel cell therapies to treat muscular dystrophies and solid tumors.

Chip Wilson, founder of Lululemon Athletica and SOLVE FSHD, said, “Having lived with FSHD for more than 30 years, I’ve had a fair amount of muscle wasting in my upper body. I hope it inspires and helps people like me build muscle faster than it breaks down.

The investment is part of a $31 million Series B funding round led by Cambrian Biopharma. In addition to joining Solve FSHD, other new investors included Riptide Ventures and Cedars Sinai, joining TEDCO and other existing investors. Proceeds from the funding will be used to advance Vita’s flagship preclinical program VTA-100 for Limb-Girdle Muscular Dystrophy (LGMD2A) into the clinic. It will also fund the development of VTA-120, Vita’s newest program for the treatment of patients with FSHD, further expanding Vita’s discovery pipeline. Since its inception, Vita has raised a total of $66 million.

“Currently, there are no treatments available for FSHD. There is an urgent need to develop disease-modifying therapies that not only regenerate muscle, but also correct the genetic defects that lead to muscle inability to self-repair,” said an executive. Eva Chin says. Director of SOLVE FSHD. “We are excited to support Vita as they continue to expand their induced pluripotent stem cell (iPSC) technology towards FSHD while furthering the treatment of LGMD.”

About SOLVE FSHD
SOLVE FSHD funds innovative biotechnology and biopharmaceutical research and development activities that advance new treatments for facioscapulohumeral muscular dystrophy (FSHD). It was wholly funded and founded by Canadian entrepreneur and philanthropist Chip Wilson. Yoga-inspired athletic He is the founder of apparel company lululemon Athletica inc. Lived with FSHD for the last 30 years of his life. He created SOLVE FSHD, a $100 million investment to accelerate research into new treatments by 2027 and begin funding projects that fit the organization’s mission of finding cures for disorders. I committed my own funds. https://solvefshd.com/

For early-stage companies, contact Solve FSHD. [email protected]

If you have FSHD and would like to learn about clinical trials or register with the FSHD Registry, please visit the Solve FSHD website – https://solvefshd.com/.

About Vita Therapeutics
Vita Therapeutics is a biotechnology company developing cutting-edge cell therapies for the treatment of debilitating neuromuscular diseases and cancer. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace defective cells in patients. The company is advancing its lead program VTA-100 for the treatment of limb girdle muscular dystrophy (LGMD2A) with the goal of submitting an investigational drug application with the U.S. Food and Drug Administration within the next 18 months. Longer term, the company is developing its cell therapy pipeline following a dual development strategy, starting with autologous cells and moving to universal low-immunogenic cell lines. Vita Therapeutics is currently working on clinical programs with a number of partners including PanCella, Wyss Institute and Johns Hopkins University. For more information about the company, please visit www.Vitatx.com.

Media contact:
Carla Bosacki, Account Director
PR Associates
[email protected]
Phone: 416-522-9677

CBJ Newsmaker